1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow F16IL2: new trials by email Literature Review of F16IL2 trials Research Report on F16IL2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer F16IL2, Nivolumab, fixed dose - Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Unknown | Philogen S.p.A. | 3 | 2017-03-09 | 2022-07-21 |
Carcinoma, Non-Small-Cell Lung (1)
Philogen S.p.A. (1)
Switzerland (1)